(株)リボミックの貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|
| 東証GRT | 医薬品 | 4591/ - | - |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|
| 2017/04/07 | 日証協 | 239,700株 | -2.36% | 11,800株 | -56.78% | 344,713株 | +1.45% | 6,800株 | -71.47% |
| 2017/03/31 | 日証協 | 245,500株 | +5.46% | 27,300株 | +141.59% | 339,781株 | -2.65% | 23,832株 | +249.44% |
| 2017/03/24 | 日証協 | 232,800株 | -1.19% | 11,300株 | +438.1% | 349,013株 | -1.22% | 6,820株 | +120% |
| 2017/03/17 | 日証協 | 235,600株 | -7.24% | 2,100株 | -71.23% | 353,313株 | -0.53% | 3,100株 | -58.11% |
| 2017/03/10 | 日証協 | 254,000株 | -2.76% | 7,300株 | -57.31% | 355,213株 | -1.17% | 7,400株 | +48% |
| 2017/03/03 | 日証協 | 261,200株 | -1.69% | 17,100株 | -15.76% | 359,413株 | +8.02% | 5,000株 | -68.55% |
| 2017/02/24 | 日証協 | 265,700株 | +1.57% | 20,300株 | +138.82% | 332,713株 | -8.55% | 15,900株 | +245.65% |
| 2017/02/17 | 日証協 | 261,600株 | -1.06% | 8,500株 | -11.46% | 363,828株 | +0.59% | 4,600株 | +38.55% |
| 2017/02/10 | 日証協 | 264,400株 | +2.68% | 9,600株 | +43.28% | 361,708株 | -0.19% | 3,320株 | -66.8% |
| 2017/02/03 | 日証協 | 257,500株 | +0.35% | 6,700株 | -62.15% | 362,408株 | +1.23% | 10,000株 | +63.53% |
| 2017/01/27 | 日証協 | 256,600株 | +3.05% | 17,700株 | +37.21% | 358,008株 | +1.16% | 6,115株 | +60.92% |
| 2017/01/20 | 日証協 | 249,000株 | +2.13% | 12,900株 | +44.94% | 353,893株 | +0.85% | 3,800株 | -28.3% |
| 2017/01/13 | 日証協 | 243,800株 | -9.77% | 8,900株 | +270.83% | 350,908株 | -2.69% | 5,300株 | +17.78% |
| 2017/01/06 | 日証協 | 270,200株 | -0.3% | 2,400株 | -42.86% | 360,608株 | -0.61% | 4,500株 | -15.33% |
| 2016/12/30 | 日証協 | 271,000株 | +4.15% | 4,200株 | -58.82% | 362,808株 | +0.92% | 5,315株 | -33.58% |
| 2016/12/22 | 日証協 | 260,200株 | -2.18% | 10,200株 | +155% | 359,493株 | -0.58% | 8,002株 | +81.04% |
| 2016/12/16 | 日証協 | 266,000株 | +2.9% | 4,000株 | -78.02% | 361,591株 | +1.49% | 4,420株 | -62.86% |
| 2016/12/09 | 日証協 | 258,500株 | +3.98% | 18,200株 | +256.86% | 356,291株 | +1.51% | 11,900株 | +169.6% |
| 2016/12/02 | 日証協 | 248,600株 | -2.85% | 5,100株 | -48.48% | 350,991株 | +0.83% | 4,414株 | +2.65% |
※株式分割は考慮していませんのでご注意ください。
Page Top